Skip to main content
impaact logo Return to homepage
  • Contact
    • Directory
  • About
    • Mission
    • Network Structure
      • Leadership
    • Areas of Research
      • HIV Complications and Co-Morbidities
      • HIV Cure
      • HIV Treatment
      • Tuberculosis
      • Social Behavioral Scientific Core (SBSC)
    • Funding Acknowledgements
    • Network Sites
      • Site Map
    • Staff Spotlights
  • Studies
    • Research and Study Opportunities
    • Submit a Research Proposal
    • IMPAACT Study Snapshots
  • Community Engagement
    • ICAB Leadership Group
    • IMPAACT Community Advisory Board (ICAB)
    • Operations Center Staff
    • Resources
      • Acronyms
    • Site Community Advisory Boards
    • Community Meetings and Webinars
  • News & Events
    • Events and Conferences
    • IMPAACT Annual Meeting
    • Newsletters
    • Past Conference Presentations
  • Resources
    • COVID-19 Resources
    • HIV/AIDS Network Coordination (HANC)
    • Lab Center
      • Laboratory Committees
      • Laboratory Guidance Documents
      • Laboratory Resources for Quality Management
      • MiLab Resources
      • Specimen Repository
    • Manual of Procedures
    • Network Logos & Templates
    • Regulatory Resources
    • Training Opportunities
    • NIH Updates
  • Publications
    • Abstracts
    • Manuscripts
  • Enter a search term.
Back to Directory

Rachel Scheckter

Email

rscheckter@fhi360.org

Phone

919-321-3540

Institution

FHI 360

Title

Clinical Research Manager

Address

FHI 360
359 Blackwell St.
Ste. 200
Durham, NC 27701
United States of America
Request an Update

Affiliated Studies

IMPAACT 2040: Phase I/II Pharmacokinetics and safety of long-acting injectable Cabotegravir and Rilpivirine in people with virally suppressed HIV-1 during pregnancy and postpartum

DAIDS Number

38953

Research Area

Treatment

Study Status

In Development

IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age

DAIDS Number

38932

Research Area

Treatment

Study Status

Pending

IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents

DAIDS Number

34150

Research Area

Treatment

P1110: Safety and PK of RAL in Neonates

DAIDS Number

11891

Research Area

Treatment

Study Status

Concluded

P1097: Raltegravir PK Study

DAIDS Number

11790

Research Area

Treatment

Study Status

Concluded
IMPAACT logo Return to homepage

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.

Stay connected with the IMPAACT Network

Follow IMPAACT

Sign up for our newsletter

Sitemap

© 2020 IMPAACT Network